Harrow Health, Inc. Stock News

Harrow's Q2 results were solid, but meeting ambitious full-year revenue guidance will require flawless execution amid recent topline misses and a challenging market. VEVYE, IHEEZO, and TRIESENCE are key growth drivers, but VEVYE's revenue must accelerate and biosimilars add complexity and legal risk to the thesis. Aggressive acquisitions have left Harrow with high debt and limited cash, making ...

We are reiterating a Buy call on Harrow, Inc. for investment, not just trading, due to strong sales growth, product launches, and market share gains. Q2 showed 30% revenue growth and a dramatic earnings beat, with margins rebounding and profitability achieved; the outlook remains bullish despite a revenue miss. VEVYE and IHEEZO are driving prescription and revenue growth, with management guidin...

Harrow, Inc. (NASDAQ:HROW ) Q2 2025 Earnings Call August 12, 2025 8:00 AM ET Company Participants Andrew R. Boll - CFO & Corporate Secretary Mark L.

Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million Cash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.

NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright's 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually.

NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close.

NASHVILLE--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter “Samsung Bioepis”) to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar...

INCHEON, Korea--(BUSINESS WIRE)-- #biosimilars--Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (Nasdaq: HROW), for Samsung Bioepis' ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTISi (ranibizumab) and OPUVIZ™ (aflibercept-yszy), a biosi...